Gilberto De Lima Lopes Jr MD, MBA, FASCO

Dr. Gilberto Lopes, a medical oncologist, is division chief and professor of clinical medicine, medical director for international programs and associate director for Global Oncology at the Sylvester Comprehensive Cancer Center at the University of Miami; he also serves as a member for the board of directors for the Union International for Cancer Control (UICC) and is Editor-in-Chief for the American Society of Clinical Oncology’s JCO Global Oncology. He previously worked at the Johns Hopkins University and was chief medical and scientific officer for the Oncoclinicas Group, the largest oncology provider in Latin America with more than 130 units and 1300 oncologists in 35 Brazilian cities. His overarching mission is to improve cancer care and control around the world. As a lead investigator in the study Keynote 42, Gilberto presented the results at ASCO's plenary session in 2018, leading to FDA approval for pembrolizumab in advanced lung cancer with PD-L1 expression.

Dr. Lopes has published more than 250 papers in journals such as the Journal of Clinical Oncology, Cancer, Nature Reviews, Lancet, Lancet Oncology and Health Affairs. In addition to delivering lectures around the world, he has been the principal, co-Principal Investigator, or steering committee member in more than 200 studies and clinical trials. 

Dr. Lopes is or has been a committee member for the International Association for the Study of Lung Cancer (IASLC), the European Society of Medical Oncology and the American Society of Clinical Oncology (ASCO), as well as an executive board member for the Latin American Cooperative Oncology Group (LACOG). 

He has also served as an expert for the International Atomic Energy Agency, the World Health Organization and the Pan-American Health Organization and advised governments, professional societies and industry on issues related to new technologies in cancer, health economics, policy-making and cancer control and treatment in low- and middle-income countries.